NCT00104273

Data

{
  "briefSummary": "The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.",
  "completionDate": null,
  "conditions": [
    "Dementia",
    "Alzheimer's Disease"
  ],
  "enrollmentCount": 376,
  "enrollmentType": "ACTUAL",
  "nctId": "NCT00104273",
  "phase": "PHASE2",
  "sponsorId": "teva-branded-pharmaceutical-products-r-d-inc",
  "startDate": "2004-08",
  "status": "COMPLETED",
  "studyType": "INTERVENTIONAL",
  "title": "A 1-Year, Double-Blind, Randomized, Placebo-Controlled, Study of Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Dementia of the Alzheimer's Type",
  "url": "https://clinicaltrials.gov/study/NCT00104273"
}

History in this collection

1. addedv1.0.0Jun 12, 2026this version